Physician profile
Mark Wayne Saunders
NPI 1629010855
$1,530.31
in general payments reported to CMS, 2019-2025
26 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $10.29 · 2022: $40.09 · 2023: $349 · 2024: $291 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.65 | 2023-2025 | Imfinzi, Enhertu, Imjudo |
| Abbvie INC. | $157.49 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $145.85 | 2019-2023 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $142.67 | 2023-2025 | Jemperli, Zejula |
| Ethicon US, LLC | $121.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $106.98 | 2023-2025 | Libtayo, Lynozyfic |
| Myriad Genetic Laboratories, INC. | $98.06 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $78.68 | 2023-2025 | |
| Janssen Biotech, INC. | $68.94 | 2024-2025 | Tecvayli, Erleada, Akeega |
| Pharmacyclics LLC, An Abbvie Company | $61.22 | 2023 | Epkinly, Imbruvica |
| Siemens Medical Solutions USA, INC. | $45.79 | 2024 | Bravos Afterloader System |
| Takeda Pharmaceuticals U.S.A., INC. | $38.76 | 2025 | Iclusig |
| Incyte Corporation | $37.15 | 2023 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $36.84 | 2019-2025 | |
| Daiichi Sankyo INC. | $27.71 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.58 | 2025 | Trodelvy |
| Tempus Ai, INC | $22.24 | 2025 | Xt Cdx |
| Exelixis INC. | $21.92 | 2025 | Cabometyx |
| Genzyme Corporation | $20.32 | 2025 | |
| Aveo Pharmaceuticals, INC. | $18.88 | 2024 | |
| Stemline Therapeutics INC. | $18.72 | 2024 | Orserdu |
| Springworks Therapeutics, INC. | $17.21 | 2025 | Gomekli |
| Blueprint Medicines Corporation | $16.80 | 2024 | Ayvakit |
| Sobi, INC | $13.58 | 2024 | |
| Taiho Oncology, INC. | $12.38 | 2022 | |
| Elekta, INC. | $10.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.